IMPORTANCE Duration of untreated psychosis (DUP) has been associated with poor outcomes in schizophrenia, but the mechanism responsible for this association is not known.
H ippocampal volume reduction is prominent in schizophrenia, 1, 2 correlates with poor outcome, [3] [4] [5] and has been linked to early progression of illness. 6, 7 Along duration of untreated psychosis (DUP) is also associated with poor outcome, 8 but a biological basis for this association has not been identified, to our knowledge. 9 Several factors, including elevated cortisol levels, inflammation, oxidative stress, decreased neurotrophic factors, and glutamatergic excitotoxic effects, have been linked to early psychosis 10 and could mediate an association between DUP and hippocampal volume loss, but evidence from longitudinal studies is lacking. Whereas the negative association of DUP with clinical course is attenuated by the initiation of antipsychotic treatment, the evidence is mixed as to whether antipsychotics contribute to loss of brain volume or protect against it. 11,12 Hence, the degree to which loss of brain volume early in treatment reflects an illness effect, a drug effect, or both is not known.
To address the question of whether hippocampal volume reduction occurs early in treatment and is associated with DUP, we measured hippocampal volumetric integrity (HVI) (inversely associated with hippocampal atrophy) 13,14 before and after initial antipsychotic treatment in medication-naive patients with first-episode psychosis (FEP) and in matched healthy controls. We hypothesized that HVI would be reduced at baseline in participants with FEP relative to controls, would decrease at a faster rate, and would be correlated with DUP. As an exploratory approach, we also measured peripheral biomarkers that reflect factors hypothesized to affect hippocampal volume in schizophrenia and examined whether these biomarkers interact with DUP to predict HVI.
Methods

Study Design and Setting
Between March 5, 2013, and October 8, 2014 , individuals with nonaffective FEP were recruited from the Shanghai Mental Health Center early psychosis program. Healthy controls groupmatched by sex, age, and educational level were recruited by advertisement. All participants were Mandarin-speaking Han Chinese individuals living in the Shanghai metropolitan area. Eligible participants with FEP met the criteria for schizophrenia or schizophreniform disorder based on the Structured Clinical Interview for DSM-IV-TR, 15 were medication naive, were experiencing a first episode of psychosis, and did not meet the criteria for any other Axis I disorder. Healthy controls were assessed using the Structured Clinical Interview for DSM-IV-TR (nonpatient version) to exclude any Axis I disorder and were also psychotropic medication naive. All participants were between the ages of 16 and 40 years; were right-handed; completed at least 9 years of school; were free of substance abuse, suicidal ideation, and unstable medical illness; and had no contraindications to magnetic resonance imaging. After baseline assessments, participants with FEP were treated by their clinicians with second-generation antipsychotics according to standard clinical practice (eAppendix 1 in the Supplement) and were invited to return for clinical assessment and magnetic resonance imaging after 8 weeks. Matched healthy controls were also invited to return at 8 weeks for a follow-up evaluation. Participants with FEP who were outpatients were contacted weekly by telephone to reinforce medication adherence; baseline and follow-up visits were scheduled as closely as possible to 8 weeks apart. The study protocol was approved by the Shanghai Mental Health Center institutional review board and the New York University Medical Center institutional review board, and all participants provided written informed consent.
Study Measures
The primary outcome was annualized change in HVI. Because the left and right hippocampi are asymmetrical in volume 16, 17 and may differ in vulnerability to disease, 18 we examined both left HVI (LHVI) and right HVI (RHVI). Participants with FEP and controls underwent imaging at Shanghai Mental Health Center at baseline and after approximately 8 weeks on a 3.0-T Siemens Verio magnetic resonance imaging scanner (Siemens) with a 32-channel head coil (eAppendix 2 in the Supplement). Hippocampal volumetric integrity, defined as the parenchymal fraction of a standardized volume of interest that is expected to encompass the hippocampus in a healthy brain, was calculated using a fully automated procedure in which the volume of interest is estimated for each hemisphere using automatically detected landmarks and the tissue fraction is estimated by histogram analysis 14 (eAppendix 3 in the Supplement). This procedure has demonstrated excellent test-retest reliability (intraclass correlation coefficient, 0.998) and superior performance compared with FreeSurfer, version 5.3.0, in differentiating individuals with Alzheimer disease from healthy age-and sex-matched controls on the basis of hippocampal volume change. 13, 14 To compare approaches, measurement of hippocampal volume was also performed using the longitudinal stream of FreeSurfer, version 6. All participants received a full psychiatric and medical screening by a research psychiatrist (B.Z.) (eAppendix 4 in the Supplement), including calculation of DUP based on history provided by the participant and family members. Duration of untreated psychosis was defined as the number of weeks elapsed since the onset of at least 1 persistent psychotic symptom of moderate or greater severity. 19 Participants with FEP also completed the Brief Psychiatric Rating
Key Points
Question Does hippocampal volume loss occur during initial antipsychotic treatment and is it associated with duration of untreated psychosis?
Findings In this longitudinal case-control study of individuals with first-episode nonaffective psychosis before and after initiation of antipsychotic medication, patients had significantly greater hippocampal atrophy compared with healthy controls at baseline. Moreover, at 8-week follow-up, hippocampal atrophy increased to a greater extent in patients compared with healthy controls, and the rate of progression of left hippocampal atrophy was significantly correlated with the duration of untreated psychosis.
Meaning Early hippocampal volume loss may play a role in mediating the association between duration of untreated psychosis and poor outcomes in schizophrenia.
Scale (BPRS) 20 and Scale for Assessment of Negative Symptoms 21 administered by a single postdoctoral rater at baseline and 8 weeks. All participants completed the MATRICS Consensus Cognitive Battery 22 at baseline and 8 weeks.
Molecular Biomarkers
Fasting blood samples and 3 saliva samples (collected in the morning, at noon, and in the evening) were obtained at baseline from the participants with FEP and controls and at week 8 from the participants with FEP (eAppendices 5-8 in the Supplement). Plasma biomarkers were selected to measure inflammation (C-reactive single-nucleotide polymorphisms associated with these pathways (eAppendix 9 in the Supplement).
Statistical Analysis
Statistical analyses were performed with SPSS software, version 23.0 (IBM Corp) and JMP Pro, version 12.2.0 (SAS Institute). All data were tested for normality of distribution using the Kolmogorov-Smirnov test. Duration of untreated psychosis, HVI, and serum biomarkers were not normally distributed. To examine between-group median differences in HVI, we used a Mann-Whitney test. To explore potential associations between DUP and biomarkers, we used Spearman rank order correlations. Normally distributed data were evaluated using the Pearson correlation coefficient, independent samples t tests, and χ 2 tests for independence. Because 4 participants received medication briefly before biomarker collection, a sensitivity analysis was performed by excluding participants who were not medication free at the time of assessment. Because the interval between imaging differed between individuals, the change from baseline in HVI was converted to an annualized rate of change. Two primary analyses were performed: comparison of HVI between groups at baseline and comparison of the annualized rate of change in HVI from baseline to follow-up between groups. Secondary analyses examined correlations between DUP and baseline HVI and between DUP and change in HVI. Confirmatory analyses were performed to examine the association of laterality with baseline HVI and change in HVI (eAppendix 10 in the Supplement). Additional exploratory analyses to assess associations between clinical measures, biomarkers, and HVI were performed without correction for multiple comparisons. These analyses were restricted to the LHVI to minimize type I error. Given the large number of predictors, and to avoid model overfitting, we applied least absolute shrinkage and selection operator (LASSO) regression 32 (eAppendix 11 in the Supplement) and limited biomarkers for multivariate modeling to those that were associated with baseline LHVI or with change in LHVI at P < .10. Least absolute shrinkage and selection operator regression is a modified form of least-squares regression that shrinks noninfluential coefficients to zero, excluding them from the final model. This approach was used owing to its robustness under conditions of nonnormality and large variable to sample size ratios, which allow for the examination of multiple interactions while minimizing the risk of type I error.
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For the 2 primary analyses, P < .03 (2-tailed) was considered significant. (Table 2 ; eFigures 1 and 2 in the Supplement). The change in LHVI and RHVI from baseline to follow-up in the controls did not differ significantly from zero. In the participants with FEP, LHVI decreased at a median annualized rate of −4.1%, and RHVI decreased at a median annualized rate of −3.3%, which differed significantly from the control group (P = .001; eFigures 3-6 in the Supplement). At baseline, neither LHVI (r = 0.04; P = .80) nor RHVI (r = 0.07; P =. 64 ) was significantly correlated with DUP; however, DUP was significantly correlated with the reduction from baseline to follow-up in LHVI (r = −0.61; P = .002) (Figure 1 ), but not with the change in RHVI (r = −0.35; P = .10). The effect of laterality was not significant for any HVI finding in participants with FEP, but baseline RHVI was larger than LHVI in controls (eAppendix 10 in the Supplement). Left and right hippocampal volume as measured by the longitudinal stream of FreeSurfer, version 6, did not differ between groups at baseline, nor did change in hippocampal volume at follow-up (eTable 4 in the Supplement).
Results
Enrollment and Retention of Participants
Peripheral Biomarkers
At baseline, median plasma aspartate and salivary cortisol concentrations were elevated in participants with FEP compared with controls; no other biomarker differed significantly between groups (Table 1) . Results did not differ when analysis was restricted to participants with FEP who were medication free at the time that blood samples were obtained (eTable 5 in the Supplement). Plasma aspartate and homocysteine concentrations increased at follow-up in participants with FEP, although the elevation in aspartate concentrations was not significant when the analysis was restricted to participants with FEP who were medication free at baseline (eTable 6 in the Supplement) and no difference between groups in biomarkers at baseline or after treatment would survive correction for multiple comparisons. Change in homocysteine concentrations was associated with change in S100B (r = 0.52; P = .004), IFN-γ (r = 0.54; P = .002), IL-8 (r = 0.47; P = .009), and tumor necrosis factor (r = 0.41; P = .03) concentrations but was not significantly associated with change in LHVI.
Antipsychotic Effects
After a mean duration of 62 days of antipsychotic treatment, individuals with FEP who completed the study showed significant improvement on the BPRS total score, the BPRS positive subscale score, the BPRS agitation subscale score, and the MATRICS Consensus Cognitive Battery composite score (eTable 7 in the Supplement). Mean daily antipsychotic dose was not significantly associated with DUP or with baseline HVI or change in HVI (eTable 8 in the Supplement). In participants with FEP, baseline LHVI was significantly correlated with RHVI (r = 0.72; P < .001), with the BPRS total score (r = −0.33; P = .014), and with the BPRS agitation subscale score (r = −0.31; P = .021) (eTable 9 in the Supplement). The change in LHVI was inversely associated with the BPRS agitation subscale score (r =−0 .4 5;P = .03) and with change in the BPRS negative symptoms subscale score (r = −0.41; P = .05), such that greater baseline agitation and less response of negative symptoms were associated with greater reduction in LHVI (eTable 10 in the Supplement). However, correlations between clinical variables and LHVI would not survive correction for multiple comparisons. Significant results of the LASSO regression models are summarized in Table 3 ; complete results can be found in eTables 11 and 12 in the Supplement, and correlational results from which factors for the LASSO regression were selected can be found in eTables 13 and 14 in the Supplement. In the first model, significant main effects associated with baseline LHVI included INF-γ, IL-8, BDNF GG genotype, and nitric oxide synthase 1 (NOS1) CC genotype. Significant interactions with DUP associated with baseline LHVI were found for INF-γ, IL-8, NOS1 CC genotype, BDNF AA genotype, zinc finger protein 804A (ZNF804A) GG genotype, and catechol-O-methyltransferase (COMT) GA genotype. In the second model, a significant main effect associated with the change in LHVI was found for S100B; interactions between DUP and S100B, thioredoxin, and NOS1 CC genotype were also associated with change in LHVI.
Discussion
Left hippocampal volumetric integrity and RHVI were reduced at baseline in participants with FEP compared with controls and decreased further during 8 weeks of treatment; this reduction in LHVI during treatment was correlated with DUP. Our exploratory analysis identified several biomarkers and genetic markers that interacted with DUP and were associated with baseline LVHI and with the change in LHVI during treatment. However, none of the plasma biomarkers that were associated with LHVI differed between patients with FEP and controls at baseline or significantly changed with treatment, so the factors that we identified as possible mediators of the effect of untreated psychosis on hippocampal volume are not clearly associated with illness or treatment.
Hippocampal Volumetric Integrity
Previous studies have not found consistent evidence of progressive hippocampal volume loss after onset of illness. 34 We found a median annualized rate of LHVI reduction of 4.1%, whereas the mean annualized reduction was 6.2%, reflecting the effect of 2 outliers with annualized LHVI reductions of 20.6% and 29.1% (Figure 2 ; eFigure 3 in the Supplement). Although the annualized rate of change in LHVI was used as a standardized unit of measure, we do not know if this rate of change would remain constant beyond the 8-week interval measured in this study. Our detection of significant change with our automated measure of HVI and not with hippocampal The solid line represents the association between ranked values for LHVI and DUP. Spearman rank correlation coefficient is shown.
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volume measured by the longitudinal stream of FreeSurfer, version 6, reflects the high reliability and sensitivity of the HVI method for detecting pathologic change, as previously demonstrated in Alzheimer disease. 14, 15 We confirmed the superior test-retest reliability of HVI in a publicly available set of repeated scans of healthy individuals; the total coefficient of variation for HVI was 0.43% vs 1.03% using the longitudinal stream of FreeSurfer, version 6 (eAppendix 13 in the Supplement). In addition, HVI is an estimate of relative (percentage) hippocampal atrophy rather than of absolute hippocampal volume and, hence, is less influenced by interindividual variability in brain volume. For example, in the current data set, HVI was markedly less correlated with intracranial volume (r = −0.19; P = .05) than was hippocampal volume measured by FreeSurfer, version 6 (r =0 . 69;P =1. 0×10 −16 ) (eAppendix 14 in the Supplement).
DUP and HVI
We found that the annualized rate of LHVI reduction increased by 0.4% per week of DUP across the full range of DUP values ( Figure 1 ). Previous studies have largely failed to identify morphologic correlates of DUP, 9,35 although in a crosssectional study, Guo and colleagues 36 found an inverse correlation between DUP and hippocampal volume. Duration of untreated psychosis was not independently associated with baseline HVI in our sample, but DUP interacted with BDNF, NOS1, COMT, and ZNF804A genotypes and with 2 inflammatory serum biomarkers in association with baseline LHVI.
HVI and Clinical Measures
At baseline, higher scores on the BPRS agitation subscale were associated with greater hippocampal atrophy (eTable 9 in the Supplement) and with greater reduction of LHVI during treatment (eTable 10 in the Supplement). Although reduced hippocampal volume may have contributed to agitation, it is also possible that stress, expressed behaviorally as agitation, contributed to hippocampal volume loss. 37 A rapid decrease in LHVI was also associated with less response of negative symptoms, suggesting a potential clinical consequence of hippocampal volume change early in treatment. However, these findings must be considered exploratory because they would not survive correction for multiple comparisons.
Peripheral Biomarkers
At baseline, we did not find differences in measures of inflammation and oxidative stress between patients and healthy controls, contrary to some other studies. 25, 38 We did find elevation of salivary cortisol concentrations in individuals with FEP, but unlike the finding by Mondelli and colleagues, 23 salivary cortisol concentration was not associated with hippocampal volume, nor were genes involved in cortisol regulation (FKBP5 and NR3C2; eTables 15 and 16 in the Supplement). In addition, aspartate concentrations were elevated at baseline among individuals with FEP. Aspartate is an excitatory neurotransmitter that acts primarily at extrasynaptic N-methyl-D-aspartate receptors that are associated with neurotoxicity 39 ; however, neither baseline aspartate concentrations nor the increase in aspartate concentrations with treatment were correlated with LHVI.
Homocysteine
Antipsychotic treatment was associated with an elevation of plasma homocysteine concentrations. Homocysteine is a neurotoxic amino acid that has been associated with hippocampal volume loss in healthy elderly individuals 40, 41 and with hippocampal injury and sensitization to oxidative stress and excitotoxic effects in animal models. 42 Homocysteine is a byproduct of dopamine metabolism by COMT, which is localized primarily in astrocytes. 43, 44 Although the elevation of homocysteine during treatment was not correlated with LHVI change, homocysteine concentrations were correlated with a marker for astrocytic injury (S100B) and with inflammatory factors (IFN-γ and IL-8) that, in turn, were correlated with LHVI.
Biomarkers Associated With Baseline LHVI
The interaction of DUP with several biomarkers was significantly associated with baseline LHVI, suggesting that they may play a role in the negative association of psychosis with hippocampal volume. These biomarkers included COMT genotype and 
Limitations
Our sample of participants with FEP was homogenous with respect to race/ethnicity and the absence of substance abuse, so these results may not generalize to more heterogeneous populations. Furthermore, 56% of participants with FEP did not complete follow-up at week 8 -this may have introduced a bias toward hospitalized patients, as indicated by the higher ratings of symptom severity in those who completed the study. It is unclear to what degree peripheral biomarkers inform us about the biochemical environment of the hippocampus because the origin of these biomarkers is not limited to the central nervous system and access to the peripheral circulation is limited by the blood-brain barrier. 10 Finally, in the absence of a placebo control, we are unable to determine from these data whether the change in HVI was the result of illness progression or a medication effect, or both. Although our results from peripheral biomarkers provide promising directions for further research on mechanisms contributing to hippocampal volume loss, these results must be considered exploratory, and the considerable heterogeneity among the participants with FEP suggests that much larger samples are needed.
Conclusions
We found significantly lower HVI at baseline in participants with FEP compared with healthy controls and additional HVI reduction during antipsychotic treatment that correlated with DUP, consistent with a persistent, possibly deleterious, effect of untreated psychosis on brain structure. Our exploratory analysis identified molecular mechanisms by which DUP may affect hippocampal volume. Larger longitudinal studies of longer duration are needed to examine the association between DUP, hippocampal volume, and clinical outcomes. 
HC baseline
The solid lines indicate individual participants with FEP; HC indicates the median LHVI value for healthy controls. Hippocampal volumetric integrity, defined as the parenchymal fraction of a standardized volume of interest that is expected to encompass the hippocampus in a healthy brain, was calculated using a fully automated procedure in which the volume of interest is estimated for each hemisphere using automatically detected landmarks and the tissue fraction is estimated by histogram analysis. 
eAppendix 3: Computation of the hippocampal volumetric integrity
Hippocampal volumetric integrity (HVI) is a normalized measure with values between 0 and 1 that is computed automatically from raw 3D T1-weighted inversion recovery structural MRI scans (henceforth referred to as 'MRI volume') without any pre-processing other than a DICOM to NIFTI format conversion. From each MRI volume two HVI values are computed; one from the left hemisphere (LHVI) and one from the right hemisphere (RHVI). HVI is intended as a surrogate marker of hippocampal atrophy and has proven highly reproducible in test-retest evaluations. It has particularly been useful in longitudinal studies for quantifying the rate of hippocampal degeneration. The rate of change of HVI, for example, predicts conversion from mild cognitive impairment to Alzheimer's disease [1] . This section provides an overview of the method for computing HVI. A software implementation of this technique (KAIBA) can be found at www.nitrc.org/projects/art. KAIBA relies on an automatic method of obtaining an affine transformation based on landmark detection of the MRI volume. The affine transformation is a composite of a 6-parameter rigid-body transformation followed by a 12-parameter structure-specific affine transformation. The 6-parameter rigid-body transformation is intended to standardize the orientation of the MRI volume. It uses published algorithms that automatically detect the brain's mid-sagittal plane (MSP) [2] and the anterior and posterior commissures (AC/PC) on the MSP [3] to obtain the transformation matrix. To obtain the 12-parameter affine transformation, a large number of landmarks (~100) in the vicinity of the structure of interest, in this case the hippocampus, are detected. The corresponding transformation matrix is then estimated by leastsquares fit of the detected landmarks to their expected average locations which have been determined a priori based on a set of example MRI volumes. Thus, the composite affine transformation (6-parameter global rigid-body and 12-parameter local affine) transforms an MRI volume into a new space designed to create a high degree of overlap between the hippocampi across subjects. Note that this procedure is performed twice, once for each hemisphere.
KAIBA uses probabilistic regions of interest (ROIs) determined based on 65 MRI volumes from young healthy individuals on which the hippocampi were manually delineated. These 65 MRI volumes were registered using the affine transformations obtained using the method described in the previous paragraph. The transformations were applied to the corresponding hippocampi labels thus projecting them onto a common space. The probabilistic ROIs are then obtained by averaging the 65 transformed labels. Again, this process is done twice, once for each hemisphere yielding two ROIs for the left and right hippocampi.
In order to determine the HVI on a test MRI volume, the first step is to determine the composite affine transformation using the landmark detection method described above. Then the inverse affine transformation is applied to the probabilistic ROI described in the previous paragraph to project the ROI onto the native space of the test MRI volume. Figure 1 shows the left ROI projected onto the space of a given test MRI volume. Since the probabilistic ROI is derived from young healthy brains, the algorithm is based on landmarks where in the native space of the test MRI volume we expect to find an intact healthy hippocampus. HVI aims to capture the extent to which this expectation is not met by the region underlying the ROI. The MRI volume itself is not adjusted in any way and no interpolation is performed on the volume because the ROI is projected onto the native space of the MRI.
In the final stage of the algorithm, KAIBA determines the histogram of the voxel intensities underlying the probabilistic ROI. The histogram is usually noisy. Therefore, a smooth function comprised of a mixture of five Gaussian curves is fitted to the histogram using the expectation maximization (EM) algorithm [4] . An example is shown in Figure 2 where the histogram of the voxel intensities comprising the left hippocampus ROI in a test volume is shown (thin blue jagged line) along with a 5-component Gaussian mixture model fit using the EM algorithm (thick red smooth line). Smooth fitting allows KAIBA to estimate the gray matter peak location I (indicated by the "Max" line) from which it determines the location of a CSF intensity threshold I (indicated by the "Thld" line). Finally, HVI is defined as the fraction of the supra-threshold voxels, or equivalently, the area under the histogram for intensities above I . More details about the algorithm can be found in [5] .
To evaluate the test-rerest reliability of KAIBA, we used data from 63 subjects from the MIRIAD public domain dataset [6] . These data were comprised of back-to-back independent MRI scans from the same subjects on the same day. We computed the HVI on these cases. The intra-class correlations (ICC) for the left and right hippocampi were 0.998 and 0.997, respectively. 
eAppendix 4: Medical and psychiatric assessments
All subjects were first assessed by study staff for capacity to participate in the study. Subjects were then assessed with the Structured Clinical Interview for DSM Disorders (SCID) to verify the diagnosis of schizophrenia or schizophreniform disorder and to exclude other Axis I diagnoses, such as psychosis due to drug use. We also completed a demographics form for each subject, a physical exam, a comprehensive medical history evaluation, a psychiatric history evaluation including past medications and hospitalizations, and vital signs assessment. We performed laboratory tests at the Screening Visit which included complete blood count, electrolytes, creatinine, BUN, glucose, liver enzymes, calcium, phosphate, magnesium, albumin, prolactin level, and urinalysis. All subjects were evaluated for drug use with a urine toxicology test and female subjects were tested for pregnancy. For inpatients, full medical evaluations from hospital records were also used to evaluate medical status to participate. eAppendix 5: Sample collection and preparation Fasting blood samples were obtained at baseline from FEP participants and healthy controls and at follow up from FEP participants. Plasma samples were obtained from venous blood using from EDTA anticoagulant and were centrifuged at 3000rpm for 20min before being frozen at -80 degree. Plasma protein quantification was performed using enzyme-linked immunosorbent assay (ELISA) or protein arrays. All samples were batched and all assays were performed in one run after completion of sample collection.
Figure 2: Histogram analysis using the EM algorithm. The histogram of the voxel intensities comprising the left hippocampus ROI in a subject is shown (thin jagged line) along with a 5-component Gaussian mixture model fit using the EM algorithm (thick smooth line). Smooth fitting allows us to estimate the gray matter peak location (indicated by the "Max" line) from which we determine the location of a CSF intensity threshold (indicated by the "Thld" line). HVI is defined as the fraction of the suprathreshold voxels, or equivalently, the area under the histogram for intensities above .
eAppendix 6: Blood biomarker assays Cytokines: The human cytokines CRP, BDNF, IL-1beta, IL-8, IFN, S100B and TNF alpha were quantified using the Customized Human Cytokine Antibody Array (RayBiotech, Norcross, GA, USA). The assay was based on the sandwich immunoassay principle and was performed according to the manufacturer's instructions by Wayen Biotechnology (Shanghai, China). In brief, antibodies targeting the selected cytokines are immobilized in specific locations on the surface of the array surface, and fifty micro liters of sample was 2-fold diluted and applied to each block in duplicate. Cytokines present in the samples are captured by the corresponding antibodies and a collection of biotinylated antibodies is added to detect the bound cytokines. The signals were visualized using fluorescent dye conjugated with streptavidin (cy3 equivalent) and were detected with a GenePix 4000B system (Axon Instruments, Foster City, CA, USA). GenePix Pro 6.0 software (Axon Instruments) was used for densitometric analysis of the spots.
Enzyme-linked immunosorbent assay (ELISA): Thioredoxin 1 (unit: pg/ml) and 5-Methyltetrahydrofolate (unit: ng/ml) were measured using specific ELISA kits (Mybiosource, Southern California, USA) based on sandwich enzyme immunoassay, with a corresponding dilution of 1:2 and 1:1 respectively. Homocysteine (unit: mol/L) was measured using an ELISA kit (Mybiosource, Southern California, USA) based on competitive enzyme immunoassay, with a dilution of 1:8. All assays were performed according to the manufacturer's instructions by Wayen Biotechnology (Shanghai, China). All samples were analyzed repeatedly (CV<20).
Colorimetric Assay: L-Lactate, L-Glutamate and L-Aspartate were quantitatively measured using specific kits (Biovision, San Francisco,USA) based on colorimetric methods. The plasma sample was directly tested as a dilution of 1:20 for L-Lactate (unit: nmol/ l) and 1:1 for L-Glutamate (unit: nmol/ l). For LAspartate (unit: nmol/ l), a 100 l plasma sample was first deproteinized by centrifuging 10 min with a 10 kDa spin filter (BioVision, San Francisco,USA) and then a 30 l deproteinized sample was directly used in the assay. All tests were performed according to the manufacturer's instructions by Wayen Biotechnology (Shanghai, China). All samples were analyzed repeatedly (CV<20%).
eAppendix 7: KASP (Kompetitive Allele Specific PCR) genotyping assays
The human SNPs of rs12742393, rs1344706, rs1360780, rs1801133, rs202676, rs2301022, rs2391191, rs2494732, rs41279104, rs4680, rs5522, rs6265, rs6490121, rs778294, rs4818, rs1801131 were tested using KASP genotyping assays (LGC, UK) performed according to the manufacturer's instructions by South Gene Technology (Shanghai, China). KASP genotyping assays were based on competitive allelespecific PCR and enable bi-allelic scoring of single nucleotide polymorphisms (SNPs) at specific loci. In brief, the KASP Assay mix contains three assay-specific non-labeled oligos: two allele-specific forward primers and one common reverse primer. The allele-specific primers each harbor a unique tail sequence that corresponds with a universal FRET (fluorescence resonant energy transfer) cassette; one labeled with FAM dye and the other with HEX dye. The KASP Master mix contains the universal FRET cassettes, ROX passive reference dye, taq polymerase, free nucleotides and MgCl2 in an optimized buffer solution. During thermal cycling, the relevant allele-specific primer binds to the template and elongates, thus attaching the tail sequence to the newly synthesized strand. The complement of the allele-specific tail sequence is then generated during subsequent rounds of PCR, enabling the FRET cassette to bind to the DNA. The FRET cassette is no longer quenched and emits fluorescence. Bi-allelic discrimination is achieved through the competitive binding of the two allele-specific forward primers. If the genotype at a given SNP is homozygous, only one of the two possible fluorescent signals will be generated. If the genotype is heterozygous, a mixed fluorescent signal will be generated. The signals were detected with a 7900HT system (Applied Biosystems, USA). SDS Software 2.3 was used for densitometric (Applied Biosystems, USA) analysis of the spots.
eAppendix 8: Salivary cortisol Three saliva samples were collected throughout the day on two consecutive days: at 8:00 AM, 12:00 AM and 20:00 PM. Participants were instructed to chew on a piece of cotton, store it in a tube. Samples were stored in the participant's home freezer until collection of 3 samples, and subsequently were sent back to our laboratory and were frozen at -80 degrees. After thawing and centrifugation at 1500rpm for 15min, cortisol levels were measured using Salimetrics High Sensitivity Salivary Cortisol ELISA KIT (Salimetrics, Suffolk, UK). The analytical sensitivity was 0.012 g /dl, and the inter-and intra-assay coefficients ranged from 3% to 7% and 3% to 11%, respectively. [1] . To explore the significant associations from the correlational analyses, LASSO regression was applied in two models: the first used LHVI at baseline and the second used change in LHVI as the dependent variable. In each model baseline values of peripheral biomarkers that correlated with baseline LHVI or with change in LHVI at a level of p< .10 were examined by LASSO regression. This permissive threshold was utilized because LASSO is more robust for detecting relationships between non-normally distributed variables than Spearman correlations and to maximize power to detect potential relationships without overloading the statistical model. Variables that were entered included baseline levels of CRP, INF , IL8, S100B, TNF , thioredoxin, DUP and the following genotypes: NOS1 (rs41279104), BDNF (rs6265), ZFN804A (rs1344706) and COMT Val158Met (rs4680). In addition, two-way interactions with DUP were examined. Results that were significant at a level of p < .05 are presented in Table 3 . Complete regression results of models of baseline LHVI and LHVI change are summarized in eTable 7 and eTable 8, respectively.
[1] Tibshirani R. Regression shrinkage and selection via the Lasso. J Royal Statis Soc, Series B (Methodological). 1996;58 (1):267-288.
eAppendix 12: Excluded subjects At baseline, images from seven FEP patients and one healthy control were excluded due to motion prior to processing. At follow up, images from one FEP patient and three healthy controls were also excluded due to motion.
eAppendix 13: Test-retest reliability comparison with FreeSurfer v.6
Macleren et al. [1] provide a unique publicly available dataset to assess the repeatability of brain segmentation and analysis methods. The dataset consists of 120 T1-weighted structural MRI volumes from 3 subjects (40 volumes/subject) acquired in 20 sessions in a span of 31 days. Each subject was scanned twice within each session, with repositioning between the two scans, allowing determination of both intra-session and inter-session test-retest reliability. The authors in [1] computed the total coefficient of variation (CV t ) for sum of left and right hippocampal volume (HV) estimated using FreeSurfer v.5.1 to be 2.92% and the intra-session coefficient of variation (CV s ) to be 2.77%. The difference CV t -CV s was not significant (p=0.41) assessed using a Monte Carlo permutation test where the scan order of all 40 volumes for each subject was randomly permutated 100,000 times.
We implemented the exact same computational procedure for the HV estimated using the longitudinal stream of FreeSurfer v.6. We calculated CV t =1.03% and CV s =1.04%. The difference CV t -CV s was not statistically significant (p=.54). We repeated the procedure for the sum of left and right hippocampal volumetric integrity (HVI) obtained using KAIBA which yielded CV t =.43% and CV s =.35%. The difference CV t -CV s was found to be statistically significant (p=.002).
There are two sources of variation in the estimated quantities: (1) the variance due to different subject positioning and random MRI noise; and (2) actual day-to-day variations, e.g., due to hydration level or time of day. The above analysis indicates that HVI (CV t =.43%) is substantially more reproducible than the HV computed using either FreeSurfer v.5.1 (CV t =2.92%) or FreeSurfer v.6 longitudinal stream (CV t =1.03%). Furthermore, the inter-session variability of HVI significantly exceeded intra-session variability (p=.002).
These results support the finding in this paper that HVI is more sensitive than FreeSurfer v.6.0 computed HV in detecting HC vs FEP group difference in hippocampus atrophy progression over the period of 8 weeks.
The means and total standard deviations for each subject and each method are given in the following table. The CV t for each subject can be obtained from these numbers. The pooled CV t reported above is obtained by taking the root-mean-square average of the CV t data from each subject as done in [1] . A source of inter-subject variance is that measurements may be associated with intra-cranial volume which is variable across subjects. To illustrate this, we computed the average hippocampal volume (HV) measured using FreeSurfer v.6 (average of left and right and both scans) and similarly the average hippocampal volumetric integrity (HVI) measured using KAIBA for all HC and FEP subjects with imaging data at baseline. We then computed the bivariate correlations between these measures and the estimated total intra-cranial volume (eTIV) obtained from FreeSurfer v.6. The HV was strongly associated with eTIV (r=.690, p<.10 -16 ), however, the association between HVI and eTIV was weaker (rs=-.19, p=.05). These results indicate HVI is less affected by inter-subject variance due difference in intra-cranial volume. Abbreviations: DUP = duration of untreated psychosis in weeks; BPRS = Brief Psychiatric Rating Scale; SANS = Scale for the Assessment of Negative Symptoms; MCCB = MATRICS Consensus Cognitive Battery; CRP = creactive protein; IQR = interquartile range; IL-1B = interleukin-1 beta; IL-8 = interleukin-8; IFN = interferon gamma; Abbreviations: BPRS = Brief Psychiatric Rating Scale; SANS = Scale for the Assessment of Negative Symptoms; MCCB = MATRICS Consensus Cognitive Battery; CRP = c-reactive protein; IQR = interquartile range; IL-1B = interleukin-1 beta; IL-8 = interleukin-8; IFN = interferon gamma; TNFa = tumor necrosis factor alpha; HCY = homocysteine; BDNF = brain derived neurotrophic factor; S100B = S100 calcium binding protein B; LHVI = left hippocampal volumetric integrity; RHVI = right hippocampal volumetric integrity. a Comparisons between FEP participants and HC were adjusted for parental education level. b Units of plasma concentration levels for all biomarkers are pg/mL except salivary cortisol which is measured in µg/dL. Abbreviations: CRP = c-reactive protein; IL-8 = interleukin-8; IFN = interferon gamma; TNFa = tumor necrosis factor alpha; S100B = S100 calcium binding protein B; DUP = duration of untreated psychosis; NOS1 = nitric oxide synthase 1; BDNF = brain derived neurotrophic factor; ZFN804A = zinc finger protein 804A; COMT = catechol-o-methyltransferase. Abbreviations: CRP = c-reactive protein; IL-8 = interleukin-8; IFN = interferon gamma; TNFa = tumor necrosis factor alpha; S100B = S100 calcium binding protein B; DUP = duration of untreated psychosis; NOS1 = nitric oxide synthase 1; BDNF = brain derived neurotrophic factor; ZFN804A = zinc finger protein 804A; COMT = catechol-o-methyltransferase. 
